Early nutritional screening may benefit patients receiving vismodegib
the ONA take:
Early nutritional screening may be beneficial in patients with locally advanced or metastatic basal cell carcinoma receiving vismodegib, a new study published online ahead of print in the journal Supportive Care in Cancer has suggested.
Although vismodegib is effective in the treatment of this type of skin cancer, weight loss and dysgeusia (persistent abnormal taste or change in taste) are common treatment-related adverse events.
Therefore, researchers sought to monitor the nutritional status of vismodegib-treated patients, as well as assess the incidence of dysgeusia and the benefit of early nutritional management.
For the prospective study, researchers enrolled 45 patients with locally advanced or metastatic basal cell carcinoma who started vismodegib between October 2011 and May 2013 at Nantes University Hospital in France.
Of those, 24 patients had not received any specific nutritional management while 21 patients were evaluated by a physician from the Nutrition Support Unit and received dietary counseling at the time of vismodegib initiation.
Results showed that 24% of patients receiving dietary counseling were undernourished at vismodegib initiation and the 6-month cumulative incidence of dysgeusia was 71%.
Researchers found that 38% of patients receiving dietary counseling experienced a weight loss greater than 5% compared with 54% of those who did not receive any specific nutritional management.
“The potential benefit of nutritional support in this setting warrants further investigation,” the authors conclude.
Early nutritional screening may be beneficial in patients with locally advanced or metastatic basal cell carcinoma receiving vismodegib.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Targeting AR Mutations Promising in Metastatic Prostate Cancer
- GUCS 2017: Early Immunotherapy Discontinuation in mRCC
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Myalgia-arthralgia Syndrome Associated With Taxanes in Patients with Breast Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|